ArticleJHEP reports : innovation in hepatology2026
TCOF1 in extracellular vesicles predicts survival in patients with HCC treated with high-dose conformal radiotherapy.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. The lack of reliable biomarkers to predict treatment response limits patient stratification and personalized therapy. Extracellular vesicles (EVs) represent a minimally invasive source of tumor-derived proteins that may reflect treatment-relevant biological changes. This study investigated EV-based protein profiling in patients with HCC undergoing high-dose conformal radiotherapy to identify prognostic biomarkers associated with treatment response and overall survival.
methodsPlasma samples from 37 patients with HCC treated with high-dose-rate interstitial brachytherapy (HDR-BT) were analyzed. EVs were isolated using EVTrap magnetic beads (Tymora Analytical, West Lafayette, IN, USA). Proteomic profiling was performed by mass spectrometry to identify differential protein expression between responders and non-responders. Statistical analyses included Fisher's exact and Mann-Whitney U tests. Survival was assessed using Kaplan-Meier and log-rank tests, and prognostic factors were evaluated by univariate and multivariate Cox regression. A two-sided p <0.05 was considered significant.
resultsA total of 2,187 unique EV proteins were identified, of which 25 showed differential expression between patients' subgroups. EV-TCOF1 (treacle ribosome biogenesis factor 1) was strongly associated with poor survival, with a hazard ratio of 6.64 (CI 2.24-19.69) and p <0.001. Multivariate analysis confirmed EV-TCOF1 as an independent predictor of overall survival. Immunohistochemistry analysis supported the tumoral origin of EV-TCOF1. External validation further demonstrated TCOF1 as a robust prognostic marker.
conclusionsEV-TCOF1 emerged as a candidate biomarker associated with therapy response and shorter overall survival in an explorative cohort of patients with HCC undergoing local high-dose conformal radiotherapy. These findings highlight the potential of EV-based proteomics as a minimally invasive tool to refine prognostic assessment in HCC and the emerging role of EV-TCOF1 specifically warrants further investigation to validate its clinical utility. IMPACT AND IMPLICATIONS: This study addresses the need for reliable, minimally invasive biomarkers to predict treatment response and survival in patients with HCC undergoing radiation therapy. As a component of liquid biopsy, circulating extracellular vesicles provide a non-invasive window into tumor biology. EV-associated TCOF1 may inform risk-adapted treatment planning, surveillance strategies, and the identification of patients who could benefit from alternative therapies. More broadly, these findings support the integration of EV-based biomarkers into translational research and the development of non-invasive approaches to personalized cancer care. CLINICAL TRIALS REGISTRATION: German Clinical Trials Register DRKS00010587.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.